phenobarbital has been researched along with Brain Damage, Chronic in 25 studies
Phenobarbital: A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.
phenobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and phenyl groups.
Brain Damage, Chronic: A condition characterized by long-standing brain dysfunction or damage, usually of three months duration or longer. Potential etiologies include BRAIN INFARCTION; certain NEURODEGENERATIVE DISORDERS; CRANIOCEREBRAL TRAUMA; ANOXIA, BRAIN; ENCEPHALITIS; certain NEUROTOXICITY SYNDROMES; metabolic disorders (see BRAIN DISEASES, METABOLIC); and other conditions.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Here we determined whether chronic administration of common AEDs during early life alters cell proliferation and neurogenesis in the hippocampus." | 1.35 | Long-term antiepileptic drug administration during early life inhibits hippocampal neurogenesis in the developing brain. ( Cai, F; Cao, J; Chen, J; Li, S; Zhang, X, 2009) |
| "A case of neuroleptic malignant syndrome (NMS) is described in a congenitally brain-damaged deaf patient." | 1.28 | Neuroleptic malignant syndrome and preexisting brain damage. ( Lazarus, A, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (56.00) | 18.7374 |
| 1990's | 8 (32.00) | 18.2507 |
| 2000's | 2 (8.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (4.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ramírez-Zamora, M | 1 |
| Veliz-Martínez, V | 1 |
| Barahona, GE | 1 |
| Mena, ID | 1 |
| Ortez, CI | 1 |
| Nolasco-Tovar, GA | 1 |
| Chen, J | 1 |
| Cai, F | 1 |
| Cao, J | 1 |
| Zhang, X | 1 |
| Li, S | 1 |
| CHAROKOPOS, S | 1 |
| SAKELLARIDES, N | 1 |
| ALLAMANES, I | 1 |
| STAURIANOS, N | 1 |
| Bjerre, I | 1 |
| Hellström-Westas, L | 2 |
| Rosén, I | 2 |
| Svenningsen, N | 1 |
| Svenningsen, NW | 2 |
| Blennow, G | 1 |
| Lindroth, M | 1 |
| Gäddlin, PO | 1 |
| Ahlström, H | 1 |
| Schain, RJ | 1 |
| Wertheim, D | 1 |
| Mercuri, E | 1 |
| Faundez, JC | 1 |
| Rutherford, M | 1 |
| Acolet, D | 1 |
| Dubowitz, L | 1 |
| Tammelleo, AD | 1 |
| Vannucci, RC | 1 |
| Perlman, JM | 1 |
| Cocito, L | 1 |
| Primavera, A | 1 |
| Montañez, S | 1 |
| Kline, AE | 1 |
| Gasser, TA | 1 |
| Hernandez, TD | 1 |
| Johnson, JD | 1 |
| Arrowsmith, WA | 1 |
| Payne, RB | 1 |
| Littlewood, JM | 1 |
| Lazarus, A | 1 |
| McNamara, ME | 1 |
| Fogel, BS | 1 |
| Ruth, V | 1 |
| Virkola, K | 1 |
| Paetau, R | 1 |
| Raivio, KO | 1 |
| Monsalve, F | 1 |
| Rucabado, L | 1 |
| Ruano, M | 1 |
| Cuñat, J | 1 |
| Lacueva, V | 1 |
| Viñuales, A | 1 |
| Lennox-Buchthal, MA | 1 |
| Liu, MC | 1 |
| Zavelson, TM | 1 |
| Debusk, FL | 1 |
| Bennett, EL | 1 |
| Rosenzweig, MR | 1 |
| Chang Wu, SY | 1 |
| Blaschke, TF | 1 |
| Berk, PD | 1 |
| Scharschmidt, BF | 1 |
| Guyther, JR | 1 |
| Vergalla, JM | 1 |
| Waggoner, JG | 1 |
| Baldwin, RL | 1 |
| Peters, JE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Protecting Brains and Saving Futures - the PBSF Protocol: a Prospective Multicenter and Observational Study on the Use of Telemedicine for Neurocritical Care in High-risk Newborns in Brazil.[NCT03786497] | 2,268 participants (Anticipated) | Observational [Patient Registry] | 2021-01-01 | Not yet recruiting | |||
| A Randomized Clinical Trial of Therapeutic Hypothermia During Transport for Hypoxic Ischemic Encephalopathy (HIE): Device-regulated Cooling Versus Standard Practice.[NCT01683383] | 101 participants (Actual) | Interventional | 2012-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Participants in target temperature range (33-34 C) anytime during transport (NCT01683383)
Timeframe: Participants will be followed for the duration of neonatal transport from the birth hospital to the cooling center, an expected average of 4 hours
| Intervention | Participants (Number) |
|---|---|
| Control (Standard Cooling) | 24 |
| Device (Servo-regulated Cooling) | 41 |
Percentage of participants in target range (33°-34°C) one hour after cooling initiation by the transport team (NCT01683383)
Timeframe: Participants will be followed for the duration of neonatal transport from the birth hospital to the cooling center, an expected average of 4 hours
| Intervention | Percentage of participants (Number) |
|---|---|
| Control (Standard Cooling) | 8 |
| Device (Servo-regulated Cooling) | 28 |
The percentage of temperatures in the target range (33°-34°C) during transport after cooling initiation by the transport team. (NCT01683383)
Timeframe: Participants will be followed for the duration of neonatal transport from the birth hospital to the cooling center, an expected average of 4 hours
| Intervention | Percentage of temperatures (Median) |
|---|---|
| Control (Standard Cooling) | 0 |
| Device (Servo-regulated Cooling) | 73 |
Time to the target temperature range (33°-34°C) from initiation of cooling by the transport team (NCT01683383)
Timeframe: Participants will be followed for the duration of neonatal transport from the birth hospital to the cooling center, an expected average of 4 hours
| Intervention | Minutes (Mean) |
|---|---|
| Control (Standard Cooling) | 63 |
| Device (Servo-regulated Cooling) | 44 |
The incidence, intervention and outcome of cardiac arrhythmia, major bleeding, altered skin integrity, pulmonary hypertension, device-related events, death, and other serious adverse events from the time of initiation of transport cooling to the time of completion will be monitored. (NCT01683383)
Timeframe: Participants will be followed for the duration of neonatal transport from the birth hospital to the cooling center, an expected average of 4 hours
| Intervention | Participants (Number) | |||||
|---|---|---|---|---|---|---|
| Cardiac arrhythmia | Major bleeding (pulmonary hemorrhage) | Altered skin integrity | Pulmonary hypertension | Device-related events | Death | |
| Control (Standard Cooling) | 0 | 0 | 0 | 0 | 0 | 6 |
| Device (Servo-regulated Cooling) | 0 | 1 | 0 | 0 | 2 | 9 |
3 reviews available for phenobarbital and Brain Damage, Chronic
| Article | Year |
|---|---|
Interventions for perinatal hypoxic-ischemic encephalopathy.
Topics: Animals; Asphyxia Neonatorum; Brain Damage, Chronic; Brain Ischemia; Calcium Channel Blockers; Excit | 1997 |
Neonatal nonhemolytic jaundice.
Topics: Bile Acids and Salts; Bile Ducts; Biliary Tract Diseases; Bilirubin; Brain Damage, Chronic; Breast F | 1975 |
Febrile convulsions. A reappraisal.
Topics: Age Factors; Animals; Animals, Newborn; Body Temperature; Brain; Brain Damage, Chronic; Child, Presc | 1973 |
2 trials available for phenobarbital and Brain Damage, Chronic
| Article | Year |
|---|---|
Early high-dose phenobarbital treatment for prevention of hypoxic-ischemic brain damage in very low birth weight infants.
Topics: Brain Damage, Chronic; Brain Ischemia; Cerebral Hemorrhage; Developmental Disabilities; Drug Adminis | 1988 |
The neurologic effects of thiopental therapy after cardiac arrest.
Topics: Adult; Aged; Brain Damage, Chronic; Clinical Trials as Topic; Critical Care; Female; Heart Arrest; H | 1987 |
20 other studies available for phenobarbital and Brain Damage, Chronic
| Article | Year |
|---|---|
[Hemicerebellitis due to chikungunya associated with refractory status epilepticus in the paediatric age].
Topics: Acute Disease; Antibodies, Viral; Anticonvulsants; Attention Deficit and Disruptive Behavior Disorde | 2020 |
Long-term antiepileptic drug administration during early life inhibits hippocampal neurogenesis in the developing brain.
Topics: Age Factors; Animals; Animals, Suckling; Anticonvulsants; Apoptosis; Brain Damage, Chronic; Carbamaz | 2009 |
[EPILEPSY IN INFANCY AND CHILDHOOD. REMARKS ON 360 PERSONAL CASES].
Topics: Adolescent; Adrenocorticotropic Hormone; Birth Injuries; Brain; Brain Damage, Chronic; Brain Disease | 1963 |
Monitoring of cerebral function after severe asphyxia in infancy.
Topics: Asphyxia; Asphyxia Neonatorum; Brain; Brain Damage, Chronic; Electroencephalography; Electrophysiolo | 1983 |
Brain-orientated intensive care treatment in severe neonatal asphyxia. Effects of phenobarbitone protection.
Topics: Asphyxia Neonatorum; Blood Transfusion; Brain Damage, Chronic; Brain Edema; Critical Care; Humans; I | 1982 |
Phenobarbital in neurologically handicapped children.
Topics: Brain Damage, Chronic; Child; Humans; Intellectual Disability; Nervous System Diseases; Phenobarbita | 1981 |
Predictive value of early continuous amplitude integrated EEG recordings on outcome after severe birth asphyxia in full term infants.
Topics: Asphyxia Neonatorum; Brain Damage, Chronic; Electroencephalography; Follow-Up Studies; Humans; Infan | 1995 |
Prognostic value of continuous electroencephalographic recording in full term infants with hypoxic ischaemic encephalopathy.
Topics: Brain Damage, Chronic; Brain Ischemia; Diagnosis, Computer-Assisted; Electroencephalography; Follow- | 1994 |
Nurses fail to keep physicians informed of multiple seizures. Case in point: Glassman v. St. Joseph Hospital 631 N.E. 2d 1186--IL (1994).
Topics: Brain Damage, Chronic; Coronary Artery Bypass; Humans; Illinois; Male; Malpractice; Nursing Staff, H | 1994 |
Vigabatrin aggravates absences and absence status.
Topics: Adult; Anticonvulsants; Asphyxia; Brain Damage, Chronic; Carbamazepine; Drug Therapy, Combination; E | 1998 |
Jury finds pharmacy's misfilling of prescription caused child's brain damage.
Topics: Brain Damage, Chronic; California; Child; Female; Humans; Liability, Legal; Medication Errors; Pharm | 1999 |
Phenobarbital administration directed against kindled seizures delays functional recovery following brain insult.
Topics: Amygdala; Animals; Anticonvulsants; Astrocytes; Brain Damage, Chronic; Cerebral Cortex; Drug Adminis | 2000 |
Comparison of treatments for congenital nonobstructive nonhaemolytic hyperbilirubinaemia.
Topics: Agar; Aspartic Acid; Bilirubin; Brain Damage, Chronic; Child, Preschool; Cholestyramine Resin; Dieta | 1975 |
Neuroleptic malignant syndrome and preexisting brain damage.
Topics: Adult; Brain Damage, Chronic; Drug Therapy, Combination; Haloperidol; Humans; Male; Neuroleptic Mali | 1992 |
Anticonvulsant-responsive panic attacks with temporal lobe EEG abnormalities.
Topics: Adolescent; Adult; Anticonvulsants; Brain Damage, Chronic; Carbamazepine; Clonazepam; Electroencepha | 1990 |
Clinical experience with sulthiame (Ospolot).
Topics: Adolescent; Adult; Anticonvulsants; Brain Damage, Chronic; Epilepsy, Temporal Lobe; Female; Humans; | 1966 |
Acute dextropropoxyphene hydrochloride (Darvon) poisoning.
Topics: Adolescent; Brain Damage, Chronic; Dextropropoxyphene; Diazepam; Female; Humans; Nalorphine; Phenoba | 1973 |
Excitant and depressant drugs modulate effects of environment on brain weight and cholinesterases.
Topics: Acetylcholinesterase; Age Factors; Animals; Brain; Brain Damage, Chronic; Cholinesterases; Dextroamp | 1973 |
Crigler-Najjar syndrome: an unusual course with development of neurologic damage at age eighteen.
Topics: Adolescent; Alkaline Phosphatase; Bilirubin; Brain Damage, Chronic; Brain Diseases; Carbon Monoxide; | 1974 |
Hematologic complications from tranquilizers in children.
Topics: Adolescent; Age Factors; Agranulocytosis; Bone Marrow Examination; Brain Damage, Chronic; Brain Dise | 1968 |